Aspirin Therapy After Ischemic Stroke Complicated by Intracranial Hemorrhage

Introduction to Aspirin Therapy

• The American Heart Association recommends that aspirin can probably be restarted within 3-7 days for non-lobar hemorrhages with strong indications, but should be delayed for a minimum of 4-6 weeks for lobar hemorrhages or when indications are less compelling 1

Critical Decision Framework

• Do NOT start aspirin within 24 hours if the patient received IV thrombolysis due to increased risk of serious intracranial bleeding complications 2, 3, 4
• Brain imaging must first exclude intracranial hemorrhage before any aspirin administration 2
• For uncomplicated ischemic stroke, aspirin 160-325 mg should be initiated within 24-48 hours of stroke onset 2, 3, 5

Risk Stratification for Hemorrhagic Complications

• High-risk features for intracranial hemorrhage recurrence include lobar location, older age, presence and number of microbleeds on gradient echo MRI, and apolipoprotein E ε2 or ε4 alleles 1
• Strong indications for aspirin include recent acute coronary syndrome, coronary stents, high-risk coronary disease, and documented high thrombotic risk 1

Timing Algorithm Based on Clinical Scenario

• Restart aspirin at 3-7 days post-intracranial hemorrhage if the patient is clinically stable and has strong antiplatelet indications 1
• Delay aspirin for a minimum of 4-6 weeks after lobar intracranial hemorrhage or when indications are less compelling 1

Dosing Considerations When Restarting

• Loading dose: 160-325 mg aspirin when initiating therapy 2, 6, 7
• Maintenance dose: 50-100 mg daily for long-term secondary prevention 6, 7

Critical Pitfalls to Avoid

• Starting aspirin within 24 hours of thrombolytic therapy significantly increases intracranial hemorrhage risk 2, 3, 4
• Urgent anticoagulation in patients with moderate-to-severe strokes carries high risk of serious intracranial hemorrhagic complications 2, 3, 4

Evidence Quality

• The recommendation for delaying aspirin after hemorrhagic transformation carries Class IIa (Level of Evidence B) from the American Heart Association, indicating moderate-quality evidence that benefits probably outweigh risks 1